Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases

Rheumatology (Oxford). 2001 Dec;40(12):1394-7. doi: 10.1093/rheumatology/40.12.1394.

Abstract

Objective: To evaluate the efficacy of treatment with pamidronate in reflex sympathetic dystrophy (RSD) refractory to previous treatment.

Methods: We studied the response (disappearance of pain and functional improvement) to pamidronate (60 mg/day for 3 days) in 29 patients with RSD refractory to previous treatment for at least 14 days.

Results: On day 45, complete pain disappearance was observed in 86.2% of patients and functional improvement in 70%. The mean delay until the pain disappeared was 20+/-14 days and the delay until functional improvement was observed was 29+/-18 days. The mean delay of functional improvement was shorter in patients with post-traumatic RSD. Multivariate analysis did not reveal any factor predictive of response to treatment. Six (20.7%) patients suffered from side-effects (fever, diarrhoea).

Conclusion: Pamidronate appeared to be effective in the treatment of refractory RSD; however, these results need to be confirmed by a controlled placebo study.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects
  • Diphosphonates / administration & dosage*
  • Diphosphonates / adverse effects
  • Female
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Pamidronate
  • Reflex Sympathetic Dystrophy / drug therapy*

Substances

  • Anti-Inflammatory Agents
  • Diphosphonates
  • Pamidronate